Asset sale Announced
AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031
US$630m consideration
Announced 20 Jan 2026
Advisers
AbelZeta's 50% share of China development and commercialisation rights to C-CAR031
Target
- Legal adviser
AstraZeneca
Acquirer
Not disclosed
- Target
- AbelZeta's 50% share of China development and commercialisation rights to C-CAR031
- Acquirer
- AstraZeneca
- Seller
- AbelZeta
- Target based in
- China
- Buyer based in
- United Kingdom
- Seller based in
- China (unverified)
- Sector
- Biotech
- Tags
- Biotech, Cell Therapy, Oncology
Similar deals
- Galera Therapeutics and Obsidian Therapeutics merger Apr 2026 · US$414m · Biotech
- Eli Lilly and Company acquisition of Kelonia Therapeutics Apr 2026 · US$7bn · Biotech
- Gilead Sciences acquisition of Arcellx Feb 2026 · US$7.8bn · Biotech
- UCB acquisition of Neurona Therapeutics Apr 2026 · US$650m · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
Sources
- 20 Jan 2026 AbelZeta sale of China rights to GPC3 CAR-T therapy to AstraZeneca davispolk.com
